Summary.-In confirmation of other studies it has been shown that antibody directed against the tumour specific transplantation-type antigens (TSTAs) cannot be detected in rats with a tumour growing intramuscularly but appears within a few days after excision of the tumour. Circulating antibody is found in the serum of rats with lymph node metastasis following excision of the primary. Absorption by the intramuscular tumour of circulating antibody does not account for the absence of antibody since the antibody levels in thoracic duct lymph in rats with tumours in the leg are also very low and rise rapidly after tumour excision. Antibody is released by the draining nodes directly into the lymph and must pass through the thoracic duct before entering the blood. Under these conditions low levels of antibody activity in lymph cannot be ascribed to absorption by the tumour.
tumour is excised. Consequently, mechanisms other than absorption by the tumour must be responsible for the absence of measurable amounts of antibody in the blood in tumour-bearing animals.
The recent finding ) that complexes of TSTA and specific antibody with soluble antigen in excess can be found in the serum of rats with sarcoma suggests that one factor responsible for the failure to detect serum antibody in the tumour-bearing animals is the release by the tumour of soluble antigen into the circulation. The experiments to be described suggest that soluble TSTA escapes not only into the circulation but also into the afferent lymph, where it combines immediately with antigen-binding cells and specific antibody formed by the plasma cells present in the draining nodes. The release and combination of soluble antigen with antibody diminish the quantity of free antibodies discharged from these nodes into the efferent lymph.
In order to carry out these investigations it was necessary to collect specimens of thoracic duct lymph over a period of several days. Consequently, a method was devised of inserting a T-piece into the thoracic duct which allows daily sampling of lymph without causing a significant imbalance in the body fluids. Antibodies directed to antigens on the surface of the tumour cell were measured principally by mixed haemadsorption with a 51Cr-labelled indicator cell.
MATERIALS AND METHODS
Inbred male hooded rats were used throughout at 12-18 weeks of age and their genetic identity was established periodically by skin grafting. A methylcholanthreneinduced fibrosarcoma (MC-I) was selected for study because of its marked antigenicity and non-crossreactivity, as judged by standard transplantation tests .
The tumours were usually passaged by trocar implant. However, in some experiments where exact cell numbers were required, single cell suspensions prepared by 0-05% trypsin, 0.05% collagenese and DNase were used. The tumour was grown intramuscularly in a hind limb and excised surgically when 2-4 cm in diameter, 14-28 days after initial transplantation. Early generations of MC-I sarcoma were stored at liquid nitrogen temperature and withdrawn at intervals for passage in syngeneic hooded rats. Tests were carried out on tumours from generation 4-8. Other chemicallyinduced tumours were used for comparison.
Sampling ofperipheral blood. The animals were bled from a tail vein at various times before and after tumour excision and the sera were frozen until tested. Each experimental group consisted of 25-40 rats and anti-TSTA antibody activity in the serum was determined on 3 different samples. The results from all animals were pooled and plotted as a single result for each day since the variation between animals was less than 10%.
Preparation of immune serum specific to the MC-I sarcoma was raised by growing viable MC-I cells intramuscularly and excising the resulting tumour surgically. Subsequently, the syngeneic rats were given repeated injections ofan (15,000rad) irradiated brei of MC-I sarcoma over 12 weeks and the rats were bled one week after the last injection.
Sampling of thoracic duct lymph.-A modification of the thoracic duct cannulation method described by Delorme et al. (1969) was designed by one of us (S.A.E.) to allow the daily sampling of lymph from rats without the undue depletion of circulating lymph occasioned by continual drainage. This new technique is simpler than the only alternative method of a thoracic duct shunt (Girardet, 1970) and allows continuous or intermittent access to a stable thoracic duct lymphatic circulation over a prolonged period.
The surgical procedures used to expose the duct were as previously described . The cannula employed was in the form of a " T " tube made by glueing a length of nylon flexible tubing (size 1, Portex) over a nick cut in the side of a short length of the same tubing. The ends of the short arm were bevelled with a scalpel at 2 mm and 5 mm from the junction. A single opening was made in the thoracic duct with scissors, and through this the 5 mm end of the T tube was introduced and pushed cephalad. The 2 mm end was then slipped under the raised flap of the same opening and pushed caudad. In this position the T tube was held in place by the natural elasticity of the duct and was further secured by silk sutures around each arm of the T. Five to 10 ml of lymph were collected from eachi animal per day in iced siliconized tubes containing 0 5 ml of heparinized buffered saline, spun at 800 g for 5 minutes and the supernatant removed. The low density f,-lipids were removed by the addition of 0-02 ml of 10% dextran sulphate and 01 ml of 1 mol/l calcium chloride per ml of sample. After 1 hour at 4°C the sample was centrifuged at 1000 g for 15 minutes, the precipitate was discarded and the protein concentration was determined by spectrophotometric absorbence at A280 nm (albumin standard).
After the supernatant was dialysed overnight against 3 changes of phosphate buffered saline (PBS) pH 7-3 at 4°C it was frozen until used for assay. All samples were tested for anti-TSTA antibody at approximately the same protein concentration. In the experiments in which the kinetics of the anti-TSTA antibody response were followed daily, samples were drawn each day from a minimum of 3 animals. The cannulated animals were rotated so that no animal was drained longer than 5 days and one sample was always obtained from an animal that had been cannulated in the previous 24 hours. All samples were tested individually for anti-TSTA antibody but the results did not vary by more than 10%/ on samples drawin on the same day; therefore they are plotted as a single point.
Measurement of antibody activity by the haemadsorption test.-The technique used was a modification of the method of Tachibana, Worst and Klein (1970) . The extenlt of linking of sheep erythrocytes (srbc) coated with anti-srbc serum and anti-globulin serum to tumour cells treated with serum or lymph was assayed by labelling the srbc with 50Cr and counting the radioactivity adherent to the cultured sarcoma cells.
The rat anti-srbc serum and the rabbit anti-rat y-globulins were prepared and the srbc were sensitized with the antisera and labelled with 5'Cr as previously described . The srbc were sensitized with a concentration of antisera (rat anti-srbc 1: 200) (rabbit anti-rat yglobulin 1: 30) which gave the highest mixed haemadsorption index (MHI) when the MC-I sarcoma cells were exposed to either MC-I immune or post-excision sera.
The sera and lymph were tested on MC-I sarcoma growing in culture (3 cm Falcon dishes) as previously described . Control sera and lymph were obtained from normal animals in addition to animals bearing unrelated tumours or after these were excised. Sera and lymph were also obtained from animals immunized with complete Freund's adjuvant or BCG. The quantity of antibody bound by the tumour cells was expressed as the mixed haemadsorption index (MHI)-counts/min from 5 'Cr in cultures MHI treated with test serum or lymph counts/min from 51Cr in cultures treated with control serum or lymph A value of the MHI of 1-3 or greater was considered significant since comparable controls of different types never gave a value greater than 1-2. All tests were carried out in triplicate and lymph and serum were routinely tested at 1: 3-5-4 dilution.
Membrane immunofluorescence assay-The indirect membrane immunofluorescence test was performed on viable single cell tumour suspensions obtained from finely minced solid tumours with 0-04% trypsip and 0-04% collagenase in the presence of a small amount of DNase . In Fig. I shows the results obtained in the mixed haemadsorption test with various dilutions of sera from rats with (a) a growing tumour; (b) 14 days after the tumour has been excised; and (c) when the excision was followed by further immunization. It is quite obvious that no significant levels of antibody could be detected in the tumourbearing serum by this test. Antibody could be detected 14 days post-excision, but only at concentrations of I: 4 or greater and the majority of the experiments were, in fact, carried ouit at a dilution of 1: 3.5. The titre in the hyperimmune serum was very much higher. The sera from approximately 30 different rats bearing an MC-1 tumour in the hind leg were tested for specific anti-MC-I sarcoma antibody and in no instance was an MHI of greater than 1-2 detected. Other control sera were tested routinely at a dilution of 1: 3 5 and in no instance was an MHI of greater than 1 2 detected (see Table I ). Cross rats studied metastasized to the draining iliac lymph nodes. In rats which were subsequently found to have such lymph node metastases, the serum antibody levels following removal of the primary were detectable but relatively low 2 weeks after tumour excision. When the nodes became palpable 3 weeks after tumour excision, anti-TSTA antibody activity was still demonstrable in the serum but disappeared somne days later. These experiments provide the only examples of the occurrence of circulating tumourspecific antibodies in rats having a progressively growing tumour. Thus, the only animals with a progressively growing tumour in which circulating anti-TSTA antibody was detectable for a considerable period of time were those with tumour growing in the lymph node. (Table JJ) . On the other hand, such tumour cells could be shown to bind antibodies specifically if exposed to the serum from animals from which a tumour had been surgically removed 14 days earlier.
DISCUSSION
Three mechanisms can be envisaged to explain the absence of antibody to TSTA in the serum of animals with progressively growing antigenic sarcomata: (1) absorption by the growing tumour of the circulating antibody; (2) failure of antibody production while the tumour is in situ as a result of immunological tolerance; (3) complexing of the antibody in the circulation by soluble TSTA from the growing tumour.
While the experiments reported do not exclude the possibility that some of the antibody produced is taken up by the solid tumour, this is clearly not the only mechanism responsible for the absence of detectable antibody in tumour-bearing animals. This is shown by the measurements of antibody level in thoracic duct lymph. The fact that this level is very low in animals with a growing tumour and rises soon after tumour excision cannot be explained by combination with the tumour since the antibody in lymph is derived directly from the stimulated node before it has had an opportunity to come into contact with the tumour. The finding that circulating antibody can be found in animals with tumours growing in the lymph nodes which would be expected to adsorb antibody from the circulation at least as effectively as tumours growing intramuscularly, also suggests that the failure to detect free antibody in animals with intramuscular tumours is unlikely to be due to direct absorption by the tumour.
-------- The possibility that the absence of antibody activity in serum of tumour bearers is due to a central failure of antibody production while the tumour is in situ (i.e., immunological tolerance) is excluded by the detection of low levels of antibody in lymph and by experiments which show that the serum of tumourbearing rats contain complexes of soluble tumour antigen and specific antibody . This hypothesis is also not consistent with the finding that animals having residual metastatic tumour growing in lymph nodes have circulating antibody in their serum, nor with the rapid rise of antibody in the lymph following tumour excision. There remains the possibility that immunological responsiveness is regulated by the presence of antigen-antibody complexes in relative antigen excess and that a partial and evanescent tolerance may occur (Sinclair and Chan, 1971) but again this would be difficult to reconcile with the rapid rise in antibody activity in the lymph after tumour removal. Following excision of the tumour, there is initially an exponential increase of the rate of specific antibody production as measured by the level in the lymph. After 8 days or so the rate of antibody production by the draining nodes falls rapidly and 14 days after excision no antibody can be detected in the lymph while the serum levels are at their maximum at this time. The fact that 14 days after amputation there is a very wide divergence in antibody levels in lymph and blood plasma is a reflection of the dynamics of antibody synthesis (cf. Gurvitch and Nikolaeva, 1971) and of the unequal partition of macromolecules between blood and lymph . Although all fractions of the plasma proteins are present in lymph, they are not present in the same proportions as in blood because proteins of high molecular weight extravasate less readily from blood to extracellular fluids.
The data presented in this paper suggest that the principal reason for failing to find antibody in the circulation of tumour-bearing animals is that soluble TSTA is released by the tumour and that the low level of specific antibody released from stimulated nodes into the lymph of tumour-bearing animals is due to its continuous complexing with free soluble antigen which drains from the tumour to the lymph nodes. That residual metastatic tumour growing in a lymph node does not initially interfere with antibody activity in the serum as effectively as does a tumour growing intramuscularly may arise from the failure of released antigen to leave the node. While the tumour in the node is small, antigen binding cells such as the dendritic reticular cells and macrophages may trap the antigen within the involved node. However, as the tumour grows the architecture of the involved nodes becomes grossly distorted and may then permit antigen to gain access to the lymph and the circulation, and neutralize the circulating antibody. Other studies with the MC-I tumour also indicate that soluble TSTA is released by the tumour and complexes with antibodies both in the blood and the lymph. Thus in the circulation of tumour-bearing animals excess free antigen and complexes of antigen-antibody were found .
Our studies suggest that there are several mechanisms by which the TSTA of the MC-J sarcoma reaches the circulation of a soluble low molecular weight (<100,000 daltons) macromolecule. Circulating TSTA was not detected if rats into which the tumour has been implanted were sufficiently immunosuppressed by whole body irradiation ) so as not to form specific antibody. This suggests that the release of the TSTA occurs as a by-product of an immune reaction. The recent demonstration by Amos, Cohen and Klein (1970) that antibody does not remain for prolonged periods of time on the surface of tumour cells maintained in tissue culture suggests that specific antibody can elute TSTA from the cell membrane.
The precipitous fall in antibody levels 1 3 in immune animals which follows the injection of 106 tumour cells which are rejected (see Fig. 4 ), is explained most readily by the release of soluble antigen into the circulation from tumour cells that are being destroyed specifically at the site of inoculation. In addition, soluble TSTA is released into the circulation following non-immunological destruction of the tumour cells. This was shown using a recently developed technique (Thomson, in course of publication) by which the blood levels of TSTA from MC-J sarcoma were measured directly by radioimmunoassay. It was found that when live tumour cells were injected into normal (i.e., non-immune) rats considerable quantities of soluble TSTA were released within 24 hours.
It is possible that the biological behaviour of antigenic tumours may be determined in part by the relative ease with which release of soluble low molecular TSTAs occur. We speculate that a rapid rate of spontaneous release of soluble TSTA-a phenomenon not apparently seen with the MC-I may facilitate escape from host control and therefore be associated with a high degree of malignancy. The MC-I tumour is relatively benign; it metastasizes in less than 100% of rats and most animals can be cured by surgical excision of the primary.
Whatever the mechanisms of release, the experiments reported show that tumour transplantation is associated with a persisting release of soluble antigen into the circulation. This antigenic burden is continuously present and continually renewed as long as the tumour mass exists and has been shown to affect the humoral immune response and might be expected to interfere also with specific cell-mediated immunological responses to the tumour. Studies by Currie and Basham (1972) and Baldwin et al. (1973) support the idea that excess antigen may act on the lymphocyte surface and impair the capacity of cytotoxic lymphocytes to kill the specific target cells. The tumour specific " blocking " factor in the serum of patients with cancer, at one time postulated to be antibody, has now been attributed to complexes of tumour antigen with antibody by Sjogren et al. (1971) . Our data draw attention to the soluble tumour antigens that escape the tumour mass and become available to interact systemically with elements of the lymphoreticular system. It is suggested, as have others (Smith, 1972) , that tumour antigen excess may be a dominant element in the tumour-host relationship.
